Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC14B | O60729 | 2/20 | 0.36 |
| ▸ | CDC14A | Q9UNH5 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20205332 | 0.97 | CDC14B (0.38) | CDC14BCDC14AALOX5PGRPRKDC | |
| SCHEMBL20205317 | 0.95 | CDC14B (0.39) | CDC14BCDC14AALOX5PRKDCCYP17A1 | |
| SCHEMBL23351968 | 0.94 | CDC14B (0.37) | CDC14BCDC14AALOX5PGRCYP17A1 | |
| SCHEMBL20205315 | 0.92 | CDC14B (0.38) | CDC14BCDC14AALOX5CYP17A1CYP19A1 | |
| SCHEMBL20205321 | 0.91 | CDC14B (0.35) | CDC14BCDC14AALOX5PGRCYP19A1 | |
| SCHEMBL24649835 | 0.91 | CDC14B (0.39) | CDC14BCDC14AALOX5PGRCYP17A1 | |
| SCHEMBL20205336 | 0.91 | CDC14B (0.40) | CDC14BCDC14AALOX5PGRCYP17A1 | |
| SCHEMBL20205324 | 0.90 | CDC14B (0.37) | CDC14BCDC14AALOX5CYP17A1CYP19A1 | |
| SCHEMBL24649678 | 0.90 | ALOX5 (0.31) | CDC14BCDC14AALOX5 | |
| SCHEMBL24649726 | 0.90 | ALOX5 (0.31) | CDC14BCDC14AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453680-B2 | Bisbenzofuran-fused indeno[1,2-B]fluorene derivatives and related compounds as materials for organic electroluminescent devices (OLED) | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | disclosed |
| EP-3544985-B1 | BISBENZOFURAN-FUSED INDENO[1,2-B]FLUORENE DERIVATIVES AND RELATED COMPOUNDS AS MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES (OLED) | MERCK PATENT GMBH (DE) | 2021-05-12 | — | — | EP | disclosed |
| WO-2018095940-A1 | BISBENZOFURAN-FUSED INDENO[1,2-B]FLUORENE DERIVATIVES AND RELATED COMPOUNDS AS MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES (OLED) | MERCK PATENT GMBH (DE) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453680-B2 | Bisbenzofuran-fused indeno[1,2-B]fluorene derivatives and related compounds as materials for organic electroluminescent devices (OLED) | OCIAD2, OCIAD1, JUND | CDC14B 3977/4885CDC14A 4435/4885ALOX5 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.